Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Simeprevir Plus Sofosbuvir (12 And 8 Weeks) In Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: Optimist-1, A Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, +8 Additional Authors
Simeprevir Plus Sofosbuvir (12 And 8 Weeks) In Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: Optimist-1, A Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, +8 Additional Authors
Journal Articles
No abstract provided.
Efficacy Of Sofosbuvir, Velpatasvir, And Gs-9857 In Patients With Hepatitis C Virus Genotype 2, 3, 4, Or 6 Infections In An Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, +14 Additional Authors
Efficacy Of Sofosbuvir, Velpatasvir, And Gs-9857 In Patients With Hepatitis C Virus Genotype 2, 3, 4, Or 6 Infections In An Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, +14 Additional Authors
Journal Articles
© 2016 AGA Institute Background & Aims Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients. Methods We performed a multicenter, open-label trial at 32 sites in the United States and 2 sites in New Zealand from …
Efficacy Of Direct-Acting Antiviral Combination For Patients With Hepatitis C Virus Genotype 1 Infection And Severe Renal Impairment Or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, +4 Additional Authors
Efficacy Of Direct-Acting Antiviral Combination For Patients With Hepatitis C Virus Genotype 1 Infection And Severe Renal Impairment Or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, +4 Additional Authors
Journal Articles
© 2016 AGA Institute. Background & Aims Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD). Methods We performed a single-arm, multicenter study of treatment-naïve adults with HCV genotype 1 infection, without cirrhosis and with CKD stage 4 (estimated glomerular filtration rate, 15-30 mL/min/1.73 m2) or …